Lead Discovery Center GmbH, Nordrhein-Westfalen, Germany
Restuan Lubis is an early-stage researcher and an industrial Ph.D. student at Lead Discovery Center GmbH, Germany. Building on the foundation and experience gained during his master's research in the Drug Design Program at University College London, United Kingdom, he successfully established an HTS-screening Technology Platform for "general" helicase inhibitors targeting DNA damage repair pathways for cancer treatment. Utilizing this platform, he conducted large-scale screenings involving millions of small molecules against various helicase protein targets and characterized the inhibitors in collaboration with eight leading European academic and commercial research institutes. During the COVID-19 pandemic, Restuan established a research start-up in Indonesia, which he managed remotely from Germany.
Disclosure information not submitted.
HTS-screening Technology Platform: Helicases Inhibitors
Wednesday, February 7, 2024
11:00 AM – 11:30 AM EST